Author, year | Population description | Country | Disease | Primary outcome | Other outcomes | Sample N | Cases N | Controls N | Notes on cohorts | Gene/locus | Conclusions | Ref. |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Lin M, 2003 | SARS cases admitted to Taipei Hospital, Taiwan | Taiwan | SARS | Manifest disease | Severity | 134 | 33 | 101 | HLA-A, HLA-B, HLA-DRB1 | HLA-B*4601 nominally associated with severity (vs larger control group), not with infection after P correction | [28] | |
Chiu RWK, 2004 | SARS patients admitted at Hong Kong Chinese University Hospital | Hong Kong | SARS | Manifest disease | Severity | 496 | 168 | 328 | ACE2 | Negative results | [29] | |
Itoyama S, 2004 | Vietnamese patients with SARS | Vietnam | SARS | Manifest disease | Hypoxemia | 147 | 44 | 103 | # | ACE | ACE nominally associated with severity | [30] |
Ng MHL, 2004 | SARS patients admitted at Hong Kong Chinese University Hospital | Hong Kong | SARS | Manifest disease | Severity | 18864 | 90 | 18774 | HLA-A, HLA-B, HLA-DR, HLA-DQ | HLA-B*0703 and -B*0301 nominally associated with the disease; no association with severity | [31] | |
Chan KC, 2005 | SARS patients previously admitted at Hong Kong Hospitals | Hong Kong | SARS | Manifest disease | Severity | 466 | 140 | 326 | ACE | Negative results | [32] | |
Hamano E, 2005 | SARS patients | Vietnam | SARS | Manifest disease | Severity (oxygen therapy) | 147 | 44 | 103 | OAS-1, MxA, PKR | Nominal association of OAS-1 with disease but not severity; nominal association of MxA with severity only | [33] | |
Ip WK, 2005 | SARS patients previously admitted at 5 Hong Kong Hospitals | Hong Kong | SARS | Manifest disease | Serum MBL level; severity (death) | 1757 | 569 | 1188 | MBL | Association of -221 Y allele with disease and MBL level; no association with mortality | [34] | |
Itoyama S, 2005 | Vietnamese patients with SARS | Vietnam | SARS | Manifest disease | 147 | 44 | 103 | # | ACE2 | Negative results | [35] | |
Yuan FF, 2005 | SARS patients admitted at Prince of Wales Hospital, Hong Kong | Hong Kong | SARS | Manifest disease | Severity (ICU or death) | 380 | 180 | 200 | § | FcγRIIA, MBL | No association with MBL; FcγRIIA nominally associated with severity | [36] |
Zhang H, 2005 | SARS patients from Bejing, China | China | SARS | Manifest disease | Serum MBL level | 744 | 352 | 392 | MBL | Association of nt 54 B allele with disease and MBL level | [37] | |
Chan VS, 2006 | SARS patients admitted at four hospitals in Hong Kong | Hong Kong | SARS | Manifest disease | 1127 | 285 | 842 | $ | CLEC4M (L-SIGN) | CLEC4M nominally associated with homozigosity (protective). Functional analysis consistent with genetic risk. | [38] | |
Chong WP, 2006 | SARS cases retrospecivelly selected in Hong Kong and Bejing, China | Hong Kong | SARS | Manifest disease | Severity (death) | 925 | 476 | 449 | IFN-γ, IL-10, TNF-α | No association with IL-10 and TNFalfa; IFNγ nominally associated with disease, not associated with severity | [39] | |
He J, 2006 | SARS patients from Bejing, China | China | SARS | Manifest disease | 66 | 66 | 64 | Cohort assessed for risk factors | OAS-1, MxA | Nominal association of OAS-1 and MxA with disease. For both variants association found in dominant model only. | [40] | |
Chen WJ, 2006 | SARS cases retrospecivelly selected from the National Taiwan database | Taiwan | SARS | Positive NPS | Manifest disease | 188 | 94 | 94 | ACE2, ACP5, ADAR, AIP, ANPEP, B2M, CAT, CCL5/RANTES, CD209, CIITA, CXCL9, CXCL10, CYP17A1, EIF2AK3, EIF2S1, EIF4G1, ESR1, FGL2, FN1, G6PD, GNB3, GPX1, GSS, HMOX1, IFNAR1, IFNAR2, IFNG, IFNGR1, IFNGR2, IL1A, IL1B, IL1RN, IL4, IL6, IL10, IL10RB, IL12A, IL15, IL18, IRF1, IRF3, IRF7, MBL2, MX1, NFRKB, OAS1, PRDX2, PRKRA, PTGS2, RelB, RFX5, RNASEL, SERPINB3, SH2DIA, SLAMF1, SOCS1, SOCS3, SOD1, TBF, TFRC, TGFB1, TLR3, TLR4, TRAF6, WSX1 | Nominal association of detectable NPS with 4 genes (IL1A, IL18, FGL2, RelB) in the patients’ cohort; no association with infection in the case-control study | [41] | |
Chen YM, 2006 | Employees of the Municipal Hoping Hospital, Taipei | Taiwan | SARS | Seropositivity | 100 | 20 | 80 | HLA-A, HLA-B, HLA-Cw, HLA-DQB1, HLA-DRB1 | HLA-Cw0801 nominally associated with SARS infection | [42] | ||
Chan KYK, 2007 | SARS patients previously admitted at 6 Hong Kong Hospitals | Hong Kong | SARS | Manifest disease | LDH level, WBC | 1723 | 817 | 906 | $ | ICAM3, FCER2, CD209 (DC-SIGN), CLEC4M (L-SIGN) | ICAM3 possibly associated with severity, via LDH level as a proxy | [43] |
Ng MW, 2007 | SARS cases retrospectively selected in Hong Kong and Bejing, China | Hong Kong | SARS | Manifest disease | Severity (ICU or death) | 1073 | 495 | 578 | CCL5/RANTES, IP-10, Mig | No association with IL-10 and Mig; CCL5/RANTES -28C > G is associated with disease (discovery cohort only) and severity (both discovery and validation cohorts). Association between CCL5/RANTES and severity was validated in an independent cohort of Chinese patients | [44] | |
Yuan FF, 2007 | SARS patients admitted at Prince of Wales Hospital, Hong Kong | Hong Kong | SARS | Manifest disease | Severity (ICU) | 350 | 152 | 198 | § | TLR2, TLR4, CD14 | No informative variant in TLR2 and TLR4; CD14 nominally associated with severity | [45] |
Li H, 2008 | SARS patients retrospectively collected | Hong Kong | SARS | Manifest disease | Severity (ICU or death) | 353 | 181 | 172 | FCER2, CLEC4G, CD209, CLEC4M (L-SIGN) | Negative results (4 genes in the C-type lectin genes cluster, chr. 19). | [46] | |
Wang S, 2008 | SARS patients admitted at Tianjin Hospital, China | China | SARS | Manifest disease | Interstitial lung fibrosis; femoral head necrosis | 208 | 75 | 133 | TNF-α | No association with infection and interstitial lung fibrosis; nominal association with femoral head necrosis | [47] | |
Xiong P, 2008 | SARS patients from Guangdong province, China | China | SARS | Manifest disease | Severity | 498 | 95 | 403 | HLA-A, HLA-B, HLA-DRB1 | Negative results | [48] | |
Keicho N, 2009 | Vietnamese patients with SARS | Vietnam | SARS | Manifest disease | Seropositivity | 145 | 44 | 101 | # | HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1 | HLA-DRB1*12 possibly associated with disease | [49] |
Wang Y, 2009 | SARS patients from Bejing and Guangzhou, China | China | SARS | Manifest disease | 899 | 376 | 523 | MASP2 | Negative results (MASP is a downstream protein of MBL). | [50] | ||
Chan KYK, 2010 | SARS patients previously admitted at Hong Kong Hospitals | Hong Kong | SARS | LDH level | 681 | 681 | n/a | $ | CD209 (DC-SIGN); combined CD209 and ICAM3 | CD209 and CD209 + ICAM3 possibly associated with severity, via LDH level as proxy | [51] | |
Ching JCY, 2010 | SARS patients previously admitted at 6 Hong Kong Hospitals | Hong Kong | SARS | Manifest disease | Severity (assisted ventilation and other not reported measures) | 1210 | 792 | 418 | $ | MxA | Nominal association of MxA with disease, not with severity; OAS-1 + MxA dyplotype also analysed | [52] |
Ng MH, 2010 | SARS patients recruited from the Hong Kong Department of Health database | Hong Kong | SARS | Manifest disease | 210 | 102 | 108 | Controls were contact of patients; families also enrolled | HLA-A, HLA-B, HLA-Cw, HLA-DQ, HLA-DR | Negative results: nominal association with disease (increase in DRB4*01010101 frequency, decrease in HLA-B*1502 and HLA-DRB3*030101 frequency in patients) not surviving to correction. Replication of previous study failed. Analysis of family data was done. | [53] | |
Wang SF, 2011 | Affected health care workers followed-up at the Dept. of Health, Taipei | Taiwan | SARS | Manifest disease | Prolonged neutralising antibody expression | 97 | 56 | 41 | HLA-B, HLA-Cw, HLA-DR | HLA-Cw1502 and DR0301 possibly associated with resistance to SARS infection | [54] | |
Yuan FF, 2014 | SARS patients admitted at Hong Kong Chinese University Hospital | Hong Kong | SARS | Manifest disease | Severity | 18950 | 176 | 18774 | 48 cases classified as severe | HLA-A, HLA-B, HLA-DR | Negative results | [55] |
Hajeer AH, 2016 | Patients with laboratory-confirmed MERS-CoV infection admitted at King Abdulaziz Medical City, Riyadh | Saudi Arabia | MERS | Manifest disease | Severity | 184 | 23 | 161 | HLA-DRB1, HLA-DQB1 | HLA-DRB1*11:01 nominally associated with severe MERS | [56] | |
Kuo CL, 2020 | COVID-19 patients from the UN Biobank | COVID-19 | COVID-19 positivity status | 323570 | 622 | 322948 | General population as control | APOE | APOE ε4 homozygous genotype associated, independent of preexisting dementia | [57] | ||
Wang W, 2020 | Donors of convalescent plasma who recovered from COVID-19 in Zhejiang, China | China | COVID-19 | Manifest disease | 3630 | 82 | 3548 | No severe case; 242 controls for HLA-DP1 locus | HLA-A, HLA-B, HLA-C, HLA-DQ, HLA-DR, HLA-DP | HLA haplotype C*07:29 and B*15:27 nominally associated with SARS-CoV-2 infection | [58] | |
Zhang Y, 2020 | Patients with COVID-19 admitted to Beijing Youan Hospital, China | China | COVID-19 | Disease severity | 80 | 80 | 24 severe cases vs 56 mild | IFITM3 | Association with severity | [59] |